Evommune, Inc. (NYSE: EVMN) announced on October 1, 2026, that it presented late-breaking data from a Phase 2a proof-of-concept trial evaluating its candidate EVO301 in adults with moderate-to-severe atopic dermatitis (AD) at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria.
EVO301 is a long-acting injectable fusion protein designed to selectively inhibit interleukin-18 (IL-18). The 70-patient trial evaluated the safety and efficacy of intravenous dosing at 5mg/kg at Baseline and Week 4. The study included 48 active patients and 22 placebo patients, with a primary endpoint assessed at Week 12, eight weeks after the final dose.
The data indicates a clear therapeutic signal, with efficacy comparable to dose-optimized marketed biologics at Week 16. The primary endpoint was met, showing a 55% least-squares mean reduction in the Eczema Area and Severity Index (EASI) from baseline at Week 12 compared to a 22% reduction in the placebo group (p<0.01). Statistically significant separation from placebo was observed as early as Week 4 and maintained through Week 12.
At Week 12, 63% of EVO301-treated patients achieved EASI-50 (partial response), compared to 23% on placebo. EASI-75 responses (near-complete clearance) reached 29% for EVO301 versus 9% for placebo. Biomarker analyses confirmed robust target engagement and broad anti-inflammatory activity across Th2, Th1, Th17, and Th22 pathways. Treatment-related adverse events occurred in 10.4% of EVO301-treated patients versus 13.6% on placebo. The company reported a favorable safety profile with no treatment-related serious or severe adverse events, no discontinuations due to adverse events, and no incidence of conjunctivitis.
Evommune stated that it plans to initiate a global Phase 2b dose-ranging trial in mid-2027 using a subcutaneous formulation of EVO301.
